AXT's Premium Multiple Prices an InP Recovery Under China's Export Control Cloud

Key Takeaways

• AXT Inc.'s Q2 2026 revenue surge was overwhelmingly driven by Indium Phosphide (InP) substrates for AI data centers, not a broader Gallium Arsenide (GaAs) recovery.
• The company's operational footprint and over half of its quarterly revenue are deeply concentrated in China, exposing the entire growth story to escalating export controls and geopolitical friction.
• The stock's elevated 30x price-to-sales multiple implies a low-risk, unconstrained InP growth trajectory that does not fully account for AXT's structural dependence on Chinese policy.

The Quarter That Ignited an InP Frenzy

AXT Inc. (AXTI), a key supplier of compound semiconductor substrates, reported a transformational second quarter of 2026, marking a dramatic inflection point in its financial trajectory. The company posted revenue of $47.6 million, an impressive 77% sequential jump from $26.9 million in Q1 2026, and a staggering 164% year-over-year increase from $18.0 million in Q2 2025. This surge propelled AXT to its highest quarterly revenue in company history. The positive momentum continued into profitability, with GAAP gross margin expanding sharply to 44.9% from 29.6% in the prior quarter and a GAAP net income of $11.1 million, a stark reversal from the losses seen throughout 2025.

This remarkable turnaround was primarily an Indium Phosphide (InP) story. InP substrate revenue reached $30.7 million, representing nearly two-thirds, or 64.5%, of total Q2 revenue. This record InP performance was explicitly linked by management to robust demand from AI data center applications, a clear sign of the market's intense focus on high-speed optical connectivity. In contrast, Gallium Arsenide (GaAs) substrates contributed a more modest $6.6 million, or 13.9% of total revenue, despite showing a sequential recovery. The market reacted swiftly to these results, sending AXT's share price from roughly $37 before the Q2 earnings call on July 30, 2026, to a peak of $88.58 by August 7, 2026. However, the stock has since pulled back, closing at $73.81 on August 10, 2026, down 16.7% on the day.

The China-Centric Business Model: A Double-Edged Blade

AXT's impressive Q2 2026 performance, particularly its InP-driven growth, is inextricably linked to its deep, and increasingly concentrated, presence in China. The company's entire wafer substrate manufacturing operation is conducted through its wholly-owned subsidiary, Tongmei, and related entities within China. Furthermore, AXT and Tongmei hold partial ownership in ten Chinese raw material companies, which supply critical inputs like gallium, arsenic, germanium, and pBN crucibles, embedding AXT's supply chain deeply within the country.

Geographically, China accounted for 62% of AXT's total revenue in fiscal year 2025, a noticeable increase from 56% in 2024 and 53% in 2023. In the most recent Q1 2026, China represented 61.7% of total sales. For Q2 2026, management explicitly stated that "China is definitely above 50% of our revenue," implying that at least $23.8 million of the quarter's $47.6 million revenue came from China-based customers. This persistent concentration is not unique to revenue; AXT's physical asset base in China was valued at $160.8 million in 2024, compared to a mere $1.35 million in North America. This reliance on China, while enabling cost advantages and proximity to a booming AI market, also creates a single point of operational and geopolitical vulnerability.

Anatomy of the Margin Leap: AI-Driven InP Dominance

The dramatic surge in AXT's profitability in Q2 2026 was largely a function of its product mix shift towards higher-margin Indium Phosphide substrates and improved manufacturing utilization. GAAP gross margins expanded impressively from 8.0% in Q2 2025 to 20.9% in Q4 2025, then accelerated to 29.6% in Q1 2026, culminating in a strong 44.9% in Q2 2026. This represents a 15.3 percentage point gain in gross margin quarter-over-quarter.

Calculating the incremental gross margin from Q1 to Q2 2026 highlights the operating leverage AXT achieved. With Q1 gross profit at approximately $7.96 million (29.6% of $26.9 million revenue) and Q2 gross profit at $21.37 million, the $20.7 million increase in revenue yielded an incremental gross profit of about $13.4 million. This works out to an incremental gross margin of roughly 64.8%, almost perfectly aligning with InP's 64.5% share of Q2 revenue. This suggests that the high-value InP products, primarily for AI data center applications, are driving virtually all of AXT's newfound profitability. As CEO Morris S. Young stated on the Q2 2026 earnings call, "Broadly, the deployment of optical connectivity in AI data centers is accelerating as hyperscalers move toward higher-speed transceiver modules." This reliance on InP, however, means that any disruption to this specific product line or its primary end-market could rapidly reverse AXT's margin gains.

The Geopolitical Tightrope: Export Controls and Tariffs

AXT's deep entrenchment in China, while a source of growth, places the company squarely on a geopolitical tightrope, particularly concerning export controls and tariffs. China initiated export controls on gallium and germanium in August 2023, requiring Tongmei to obtain permits for GaAs and Ge substrate exports. The risk escalated significantly on February 4, 2025, when China added indium phosphide substrates to its export control list, making all three of AXT's core wafer substrate families subject to export permits from China's Ministry of Commerce (MOFCOM).

The uncertainty surrounding these permits is a constant point of friction. As CFO Gary L. Fischer emphasized on the Q2 2026 earnings call, "we cannot predict the future timing of permits or success in obtaining them for any specific customer or individual order." This means that even with robust demand and manufacturing capacity, AXT's ability to ship to non-China customers is contingent on the Chinese government's licensing decisions. The impact can be material; a revenue guidance cut for Q4 2025 was directly attributed to "fewer export control permits for indium phosphide."

Beyond export controls, U.S. tariffs on Chinese-origin goods have also historically impacted AXT. Rates escalated to as high as 70% by March 2025 on some categories, affecting AXT's ability to serve North American customers competitively. This is reflected in North America's negligible contribution of approximately 2% to AXT's 2025 revenue. Furthermore, the withdrawal of Tongmei's STAR Market IPO in China, and a pivot to a Hong Kong listing, has created a potential $49 million redemption right for private equity investors, tying a substantial cash outflow to Chinese capital markets policy.

A Stretched Valuation Over a Fragile Base

AXT's dramatic re-rating since Q2 2026 earnings has pushed its valuation multiples to exceptionally high levels, suggesting the market is pricing in an aggressive growth narrative that may not fully account for underlying risks. As of August 10, 2026, AXT trades at a trailing 12-month (TTM) price-to-sales (P/S) ratio of 29.85x. This is significantly above the TTM P/S of 10.35x for a larger, more diversified photonics peer like Coherent Corp. (COHR), indicating AXT trades at nearly three times its peer's revenue multiple. Similarly, AXT's TTM EV/EBITDA of 280.79x dwarfs Coherent's 61.31x.

These stretched multiples become even more pronounced when considering AXT's still-fragile fundamental base. The company's TTM earnings per share (EPS) stands at a mere $0.07, translating to an astronomical TTM P/E of 3088.28x. AXT's net margin for the trailing twelve months is just 3.2%, and it recorded negative free cash flow per share of -$0.46. While Q2 2026 marked a return to profitability, it followed multiple quarters of losses throughout 2025, including a 11.1% revenue decline year-over-year for the full year. The market appears to be capitalizing future InP capacity targets and potential revenue streams far in advance, largely disregarding the company's historical performance and the significant geopolitical overhang. If this premium multiple were to revert toward a more normalized 10x P/S, even with steady TTM revenue, AXT's market capitalization could compress by roughly two-thirds.

Wall Street’s Split Verdict

The investment community holds a notably wide range of opinions on AXT, reflecting the tension between its high-growth InP opportunity and its concentrated geopolitical risks. Out of five analysts covering the stock over the past three months, the average price target sits at $90.75, implying an upside of approximately 22.9% from the current $73.81 share price. However, this average masks significant dispersion.

The highest target of $125.00 from Northland Securities suggests a highly optimistic outlook on AXT's InP growth and its ability to navigate geopolitical headwinds. Conversely, B. Riley Securities maintains a more cautious stance with a $55.00 price target, representing a potential downside of 25.5% from the current level. The median target of $93.00, closer to the higher end of the range, indicates that the prevailing sentiment among analysts leans bullish, likely swayed by the strong Q2 2026 results and the AI-driven demand for InP. This wide $70 spread between the low and high targets, or 127% of the low target, underscores the substantial disagreement on the company's forward risk/reward profile. Most targets were updated in late July 2026, immediately post-earnings, suggesting they reflect the Q2 strength but might not fully incorporate the long-term implications of China's evolving regulatory landscape.

The Strongest Objection: Is Diversification a Viable Path?

The most compelling argument against a bearish outlook on AXT's China concentration is management's stated intention to diversify its revenue base and the existence of long-term supply agreements (LTSAs) with major non-China OEMs. Management has indicated a long-term expectation for China to represent 40-60% of revenue, suggesting a desire to reduce its over-50% exposure. Furthermore, AXT has secured LTSAs and prepayments with global players like Lumentum and Coherent, signaling demand from diversified customers in Europe, Japan, and the U.S. Permits for InP shipments to some European and Japanese customers have already been obtained, demonstrating that cross-border trade, though complex, is possible. These steps could theoretically de-risk AXT's reliance on China and smooth out permit-related revenue volatility.

However, a closer look reveals that this diversification is more aspirational than actual, and the underlying risk mechanism remains unchanged. While LTSAs secure demand, the critical flaw is that all of AXT’s wafer substrates are still manufactured in China. This means that every single InP, GaAs, or Ge wafer shipped out of China, regardless of the customer's domicile, requires a MOFCOM export permit. The "cannot predict the future timing of permits or success" quote explicitly states this ongoing vulnerability. China's share of AXT's revenue has not meaningfully diversified; instead, it has steadily grown from 39% in 2022 to 62% in 2025, and remained "above 50%" in Q2 2026. North America, a key market for diversification, still only accounts for roughly 2% of revenue. Therefore, while strategic partnerships are positive, the operational and revenue concentration in China has yet to fundamentally shift, and the permit regime remains a critical choke point for non-China sales. A sustained reduction of China's revenue share below 40% over the next two fiscal years, coupled with strong total revenue growth, would be the primary data point to invalidate this core objection.

The Verdict on AXT's Geopolitical Premium

AXT Inc. is at a pivotal juncture, riding a powerful wave of AI-driven demand for Indium Phosphide substrates. The Q2 2026 results undeniably demonstrate a significant operational turnaround, with record revenue and a dramatic expansion in gross margins, fundamentally altering its short-term financial trajectory. However, the market's enthusiastic re-rating, pushing the stock to a premium 30x price-to-sales multiple, appears to overcapitalize this growth while significantly underpricing the company's acute geopolitical risk profile. AXT remains structurally dependent on China, both as its primary manufacturing base and as the source of over half its revenue. This concentration, exacerbated by an unpredictable export-permit regime for its core products and escalating U.S.-China trade tensions, makes its growth highly vulnerable to policy shifts beyond management's control.

Given this imbalance, our stance on AXT is Neutral, but with a clear understanding of the embedded volatility. The potential for continued InP-driven growth is compelling, but the unmitigated China exposure presents an outsized risk to the current valuation. An entry zone for a more balanced risk-reward profile would be closer to the $60-$65 range, aligning with the stock's consolidation after its initial post-earnings surge. Our 12-month target for AXT is $80.00, reflecting a discount to the analyst consensus average to account for the geopolitical premium and the persistent risk of export control or tariff-related shocks. This target implies a still-robust 20x forward price-to-sales multiple, acknowledging the InP opportunity without fully discounting the China liability. This thesis would be invalidated if AXT's China revenue share consistently rises above 70% in the next two quarters, or if non-China InP shipments face material, persistent permit delays leading to significant revenue misses. The true test for AXT will be its ability to not just grow, but to diversify its geopolitical footprint, or face the consequences of a highly concentrated and politically sensitive revenue stream.

---

Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.